the evolving treatment paradigm for braf v600e-mutant mcrc
Published 2 years ago • 315 plays • Length 2:28Download video MP4
Download video MP3
Similar videos
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
0:31
evolving treatment algorithms in colorectal cancer
-
1:17
treatment approaches for braf v600e mutant metastatic colorectal cancer
-
2:56
treating braf v600e-mutant nsclc with dabrafenib and trametinib
-
1:35:47
braf-mutated mcrc: from diagnosis to treatment
-
1:24
fire-4.5: folfoxiri plus either bevacizumab or cetuximab as 1l treatment of braf v600e-mutant mcrc
-
2:44
the rationale behind the addition of immuntherpay to tkis in treating brafv600e mutated mcrc
-
9:16
changing treatment paradigm for braf-mutant nsclc
-
44:30
new advances in treatments for colorectal cancer
-
11:54
debate: targeted therapy for ras/braf wt left sided colon cancers - bevacizumab or egfr antibodies
-
44:47
biomarker driven treatment of metastatic colorectal cancer
-
1:05
how will the paradigm trial change the mcrc treatment landscape?
-
10:08
impact of braf-v600e mutation on the tumour microenvironment and associated genomic alterations ...
-
5:19
targeting braf v600e in metastatic colorectal cancer: where are we today?
-
1:49
what is a braf-v600e mutation?
-
1:09
dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
-
1:06
scott kopetz, md, explains how braf mutations figure into treatment algorithms for crc
-
1:05
dr. morris on treatment advances made in braf-mutated mcrc
-
6:23
encorafenib, binimetinib, and cetuximab in braf v600e–mutated colorectal cancer
-
0:38
what’s next for patients with braf vj600e mutant metastatic crc?
-
6:06
colorectal cancer debate: first line braf v600e - targeted triplet
-
2:38
evolving treatment paradigms in mrcc